Mark Lomax
Research Subjects
Mark Lomax has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Alberto Papi
University of Ferrara, S. Anna University Hospital, Ferrara, Italy
1 shared publication - Bärbel Huber
Inamed GmbH, Robert-Koch-Allee 29, Gauting, Germany
1 shared publication - Claudius Kietzig
Inamed GmbH, Robert-Koch-Allee 29, Gauting, Germany
1 shared publication David Bell
BioKinetic Europe Limited , Belfast, Northern Ireland
1 shared publication- David Price
Observational and Pragmatic Research Institute Singapore Singapore
1 shared publication - Dominik Kappeler
Inamed GmbH, Robert-Koch-Allee 29, Gauting, Germany
1 shared publication
Latest Publications
- Open Access
- 1 February 2019
- Published by Taylor & Francis in Journal of Pain Research
- Vol. ume 12, 689-700
Low-dose methoxyflurane analgesia in adolescent patients with moderate-to-severe trauma pain: a subgroup analysis of the STOP! study
Introduction: The undertreatment of acute pain presents a significant challenge in the Emergency Department. This post hoc subgroup analysis of a previously reported randomized controlled UK study reports the efficacy and safety of low-dose methoxyflurane analgesia in treating adolescent patients with moderate-to-severe trauma pain. Patients and methods: Three hundred patients (96 in the adolescent subgroup) aged ≥12 years requiring analgesia for acute trauma pain (pain score of 4–7 on the Numerical Rating Scale) at triage were randomized 1:1 to methoxyflurane (up to 6 mL) or placebo (normal saline), both administered using a Penthrox® inhaler. The patient could request rescue medication (paracetamol/opioids) at any time. The primary endpoint was the change from baseline in visual analog scale (VAS) pain intensity. Results: Mean VAS pain score for the adolescent subgroup at baseline was ~61 mm. Adjusted mean change in VAS pain intensity from baseline to 5, 10, 15, and 20 minutes was −24.5, –28.1, –31.6, and –31.7 mm for methoxyflurane and −14.6, –18.8, –19.2, and –23.7 mm for placebo, with a statistically significant treatment effect in favor of methoxyflurane overall across all four time points (–9.9 mm; 95% CI: −17.4, –2.4 mm; P=0.0104). Median time to first pain relief was significantly shorter with methoxyflurane (1 minute) than placebo (3 minutes, PConclusion: This subgroup analysis shows that low-dose inhaled methoxyflurane is a rapid-acting and effective analgesic in adolescent patients presenting with moderate-to-severe trauma pain. Trial registration: Clinicaltrials.gov identifier: NCT01420159, EudraCT number: 2011-000338-12.
- 1 February 2019
- Published by Taylor & Francis in Journal of Pain Research
- Vol. ume 12, 689-700
Open AccessLow-dose methoxyflurane analgesia in adolescent patients with moderate-to-severe trauma pain: a subgroup analysis of the STOP! study
Introduction: The undertreatment of acute pain presents a significant challenge in the Emergency Department. This post hoc subgroup analysis of a previously reported randomized controlled UK study reports the efficacy and safety of low-dose methoxyflurane analgesia in treating adolescent patients with moderate-to-severe trauma pain. Patients and methods: Three hundred patients (96 in the adolescent subgroup) aged ≥12 years requiring analgesia for acute trauma pain (pain score of 4–7 on the Numerical Rating Scale) at triage were randomized 1:1 to methoxyflurane (up to 6 mL) or placebo (normal saline), both administered using a Penthrox® inhaler. The patient could request rescue medication (paracetamol/opioids) at any time. The primary endpoint was the change from baseline in visual analog scale (VAS) pain intensity. Results: Mean VAS pain score for the adolescent subgroup at baseline was ~61 mm. Adjusted mean change in VAS pain intensity from baseline to 5, 10, 15, and 20 minutes was −24.5, –28.1, –31.6, and –31.7 mm for methoxyflurane and −14.6, –18.8, –19.2, and –23.7 mm for placebo, with a statistically significant treatment effect in favor of methoxyflurane overall across all four time points (–9.9 mm; 95% CI: −17.4, –2.4 mm; P=0.0104). Median time to first pain relief was significantly shorter with methoxyflurane (1 minute) than placebo (3 minutes, PConclusion: This subgroup analysis shows that low-dose inhaled methoxyflurane is a rapid-acting and effective analgesic in adolescent patients presenting with moderate-to-severe trauma pain. Trial registration: Clinicaltrials.gov identifier: NCT01420159, EudraCT number: 2011-000338-12.
- 18 May 2018
- Published by Morressier GmbH
09 / Global medication performance and safety of methoxyflurane analgesia in patients with severe acute trauma pain treated in the emergency department: a sub-analysis of a randomised, double-blind, placebo-controlled UK study
Background Low-dose methoxyflurane administered via a handheld inhaler (Penthrox®) has been used for over 40 years in Australia and New Zealand f |
- 18 May 2018
- Published by Morressier GmbH
09 / Global medication performance and safety of methoxyflurane analgesia in patients with severe acute trauma pain treated in the emergency department: a sub-analysis of a randomised, double-blind, placebo-controlled UK study
Background Low-dose methoxyflurane administered via a handheld inhaler (Penthrox®) has been used for over 40 years in Australia and New Zealand f |
- Open Access
- 1 May 2018
- Published by Elsevier in Respiratory Medicine
- Vol. 138, 107-114
Pulmonary deposition of fluticasone propionate/formoterol in healthy volunteers, asthmatics and COPD patients with a novel breath-triggered inhaler
- 1 May 2018
- Published by Elsevier in Respiratory Medicine
- Vol. 138, 107-114
Open AccessPulmonary deposition of fluticasone propionate/formoterol in healthy volunteers, asthmatics and COPD patients with a novel breath-triggered inhaler
- 1 December 2017
- Published by SAGE Publications in Journal of Aerosol Medicine and Pulmonary Drug Delivery
- Vol. 30 (6) , 425-434
A Randomized, Crossover Trial Evaluating Patient Handling, Preference, and Ease of Use of the Fluticasone Propionate/Formoterol Breath-Triggered Inhaler
Background: Appropriate inhaler selection is of fundamental importance in obstructive lung disease management. Key factors in device selection include a patient's capacity to operate a particular device and their preference for it. Methods: This randomized, open-label, two-period, crossover study (NCT01739387) compared the ability of adolescent and adult patients with obstructive lung disease to correctly handle the fluticasone propionate/formoterol fumarate (FP/FORM; Flutiform®) pressurized metered-dose inhaler (pMDI) and FP/FORM K-haler®, a novel breath-triggered inhaler (BTI), following a simple, standardized training regimen. The primary endpoint was the ability to perform all steps correctly at the first attempt. Secondary endpoints included the ability to perform all critical steps correctly at the first attempt, the requisite number of attempts to successfully use the inhaler, the ability to be trained within 15 minutes, and the ability to trigger the K-haler BTI to actuate at the first attempt. Ease of device use and device preference versus patients' usual maintenance inhalers were also assessed. Results and Conclusions: At the first attempt, an identical proportion (77.2% [95% confidence interval [CI]: 72.1, 81.8]) of 307 patients performed all pMDI and K-haler BTI handling steps correctly, whereas the corresponding proportions performing all critical steps correctly were 82.4% (95% CIs: 77.7, 86.5) and 87.0% (95% CI: 82.7, 90.5), respectively. For both devices, >90% of patients required only two attempts to master device usage; >99% of patients could be trained to correctly use each device within 15 minutes. Virtually all patients (99.0% [95% CIs: 97.2, 99.8]) were able to successfully trigger the K-haler BTI's dose-release mechanism at first attempt. Ease of use and preference data for FP/FORM pMDI challenged the perceived wisdom that dry powder inhalers are necessarily simpler to use, whereas the corresponding data for FP/FORM K-haler strongly favored this novel BTI over the Turbuhaler®, Accuhaler®, and other pMDIs.
- 1 December 2017
- Published by SAGE Publications in Journal of Aerosol Medicine and Pulmonary Drug Delivery
- Vol. 30 (6) , 425-434
A Randomized, Crossover Trial Evaluating Patient Handling, Preference, and Ease of Use of the Fluticasone Propionate/Formoterol Breath-Triggered Inhaler
Background: Appropriate inhaler selection is of fundamental importance in obstructive lung disease management. Key factors in device selection include a patient's capacity to operate a particular device and their preference for it. Methods: This randomized, open-label, two-period, crossover study (NCT01739387) compared the ability of adolescent and adult patients with obstructive lung disease to correctly handle the fluticasone propionate/formoterol fumarate (FP/FORM; Flutiform®) pressurized metered-dose inhaler (pMDI) and FP/FORM K-haler®, a novel breath-triggered inhaler (BTI), following a simple, standardized training regimen. The primary endpoint was the ability to perform all steps correctly at the first attempt. Secondary endpoints included the ability to perform all critical steps correctly at the first attempt, the requisite number of attempts to successfully use the inhaler, the ability to be trained within 15 minutes, and the ability to trigger the K-haler BTI to actuate at the first attempt. Ease of device use and device preference versus patients' usual maintenance inhalers were also assessed. Results and Conclusions: At the first attempt, an identical proportion (77.2% [95% confidence interval [CI]: 72.1, 81.8]) of 307 patients performed all pMDI and K-haler BTI handling steps correctly, whereas the corresponding proportions performing all critical steps correctly were 82.4% (95% CIs: 77.7, 86.5) and 87.0% (95% CI: 82.7, 90.5), respectively. For both devices, >90% of patients required only two attempts to master device usage; >99% of patients could be trained to correctly use each device within 15 minutes. Virtually all patients (99.0% [95% CIs: 97.2, 99.8]) were able to successfully trigger the K-haler BTI's dose-release mechanism at first attempt. Ease of use and preference data for FP/FORM pMDI challenged the perceived wisdom that dry powder inhalers are necessarily simpler to use, whereas the corresponding data for FP/FORM K-haler strongly favored this novel BTI over the Turbuhaler®, Accuhaler®, and other pMDIs.
- 1 February 2015
- Published by Elsevier in Respiratory Medicine
- Vol. 109 (2) , 208-217
Efficacy of fluticasone propionate/formoterol fumarate in the treatment of asthma: A pooled analysis
- 1 February 2015
- Published by Elsevier in Respiratory Medicine
- Vol. 109 (2) , 208-217
Efficacy of fluticasone propionate/formoterol fumarate in the treatment of asthma: A pooled analysis